
Kristina M. Hellman
Examiner (ID: 15528, Phone: (571)272-2836 , Office: P/1675 )
| Most Active Art Unit | 1654 |
| Art Unit(s) | 1654, 1675 |
| Total Applications | 862 |
| Issued Applications | 479 |
| Pending Applications | 110 |
| Abandoned Applications | 288 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19343630
[patent_doc_number] => 20240252593
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => ASSESSING AND TREATING OBESITY
[patent_app_type] => utility
[patent_app_number] => 18/562949
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34770
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562949
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562949 | ASSESSING AND TREATING OBESITY | May 19, 2022 | Pending |
Array
(
[id] => 19977178
[patent_doc_number] => 12344639
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Chimeric gas vesicle and protein expression system therefor
[patent_app_type] => utility
[patent_app_number] => 17/749615
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 12
[patent_no_of_words] => 2396
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749615
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/749615 | Chimeric gas vesicle and protein expression system therefor | May 19, 2022 | Issued |
Array
(
[id] => 19246833
[patent_doc_number] => 20240197817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => COMPOSITIONS FOR TREATING AUTOIMMUNE, ALLOIMMUNE, INFLAMMATORY, AND MITOCHONDRIAL CONDITIONS, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/562703
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6975
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562703
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562703 | COMPOSITIONS FOR TREATING AUTOIMMUNE, ALLOIMMUNE, INFLAMMATORY, AND MITOCHONDRIAL CONDITIONS, AND USES THEREOF | May 19, 2022 | Pending |
Array
(
[id] => 19359345
[patent_doc_number] => 20240261379
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => COMPOSITION COMPRISING PEDF-DERIVED SHORT PEPTIDE, PREPARATION METHOD THEREOF, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/562810
[patent_app_country] => US
[patent_app_date] => 2022-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7263
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562810
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562810 | COMPOSITION COMPRISING PEDF-DERIVED SHORT PEPTIDE, PREPARATION METHOD THEREOF, AND USE THEREOF | May 18, 2022 | Pending |
Array
(
[id] => 19331363
[patent_doc_number] => 20240245793
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => PSD-95 INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/559157
[patent_app_country] => US
[patent_app_date] => 2022-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16143
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559157
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/559157 | PSD-95 INHIBITORS AND USES THEREOF | May 11, 2022 | Pending |
Array
(
[id] => 18177205
[patent_doc_number] => 20230037934
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
[patent_app_type] => utility
[patent_app_number] => 17/731371
[patent_app_country] => US
[patent_app_date] => 2022-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731371
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/731371 | Insulin glargine/lixisenatide fixed ratio formulation | Apr 27, 2022 | Issued |
Array
(
[id] => 17790301
[patent_doc_number] => 20220249392
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => SURFACTANT PEPTIDE NANOSTRUCTURES AND USES THEREOF IN DRUG DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/722357
[patent_app_country] => US
[patent_app_date] => 2022-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7145
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722357
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/722357 | Surfactant peptide nanostructures and uses thereof in drug delivery | Apr 16, 2022 | Issued |
Array
(
[id] => 20279405
[patent_doc_number] => 20250304647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-02
[patent_title] => Use Of Long-Acting Growth Hormone For Treating Inflammation-Induced Diseases
[patent_app_type] => utility
[patent_app_number] => 18/552656
[patent_app_country] => US
[patent_app_date] => 2022-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27117
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552656
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/552656 | Use Of Long-Acting Growth Hormone For Treating Inflammation-Induced Diseases | Mar 30, 2022 | Pending |
Array
(
[id] => 18673004
[patent_doc_number] => 20230310467
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/709609
[patent_app_country] => US
[patent_app_date] => 2022-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709609
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/709609 | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19 | Mar 30, 2022 | Abandoned |
Array
(
[id] => 19156112
[patent_doc_number] => 20240148819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => COMPOUNDS FOR USE IN THE TREATMENT OF SINUSITIS, PNEUMONIA OR OTITIS
[patent_app_type] => utility
[patent_app_number] => 18/546799
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14794
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 210
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546799
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/546799 | COMPOUNDS FOR USE IN THE TREATMENT OF SINUSITIS, PNEUMONIA OR OTITIS | Mar 17, 2022 | Pending |
Array
(
[id] => 17881194
[patent_doc_number] => 20220296671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING
[patent_app_type] => utility
[patent_app_number] => 17/680842
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15525
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680842
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680842 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | Feb 24, 2022 | Abandoned |
Array
(
[id] => 17595337
[patent_doc_number] => 20220144910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 Fc FUSION PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/583891
[patent_app_country] => US
[patent_app_date] => 2022-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 268514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -54
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583891
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/583891 | DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 Fc FUSION PROTEINS | Jan 24, 2022 | Abandoned |
Array
(
[id] => 17748262
[patent_doc_number] => 20220226465
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => Coronavirus Immunogenic Compositions, Methods and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/648283
[patent_app_country] => US
[patent_app_date] => 2022-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 106139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17648283
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/648283 | Coronavirus Immunogenic Compositions, Methods and Uses Thereof | Jan 17, 2022 | Pending |
Array
(
[id] => 18413155
[patent_doc_number] => 11667688
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Glucagon derivative and a composition comprising a long acting conjugate of the same
[patent_app_type] => utility
[patent_app_number] => 17/576519
[patent_app_country] => US
[patent_app_date] => 2022-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 17722
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576519
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/576519 | Glucagon derivative and a composition comprising a long acting conjugate of the same | Jan 13, 2022 | Issued |
Array
(
[id] => 19462477
[patent_doc_number] => 20240316146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => METHODS OF REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 18/260677
[patent_app_country] => US
[patent_app_date] => 2022-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37083
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -121
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260677
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/260677 | METHODS OF REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER | Jan 6, 2022 | Pending |
Array
(
[id] => 19411799
[patent_doc_number] => 12077606
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-03
[patent_title] => Cyclic peptide analogs and conjugates thereof
[patent_app_type] => utility
[patent_app_number] => 17/560105
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 39009
[patent_no_of_claims] => 41
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 461
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560105
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/560105 | Cyclic peptide analogs and conjugates thereof | Dec 21, 2021 | Issued |
Array
(
[id] => 18938189
[patent_doc_number] => 20240033328
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => ACTH IN THE TREATMENT OF AN ADRENOCORTICOTROPIC HORMONE RESPONSIVE PEDIATRIC DISORDER
[patent_app_type] => utility
[patent_app_number] => 18/257500
[patent_app_country] => US
[patent_app_date] => 2021-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6472
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257500
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/257500 | ACTH IN THE TREATMENT OF AN ADRENOCORTICOTROPIC HORMONE RESPONSIVE PEDIATRIC DISORDER | Dec 16, 2021 | Pending |
Array
(
[id] => 19425082
[patent_doc_number] => 12084485
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/553381
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 12
[patent_no_of_words] => 52770
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 277
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553381
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/553381 | Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use | Dec 15, 2021 | Issued |
Array
(
[id] => 18970440
[patent_doc_number] => 20240050532
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => METHODS OF TREATING DIABETES
[patent_app_type] => utility
[patent_app_number] => 18/266706
[patent_app_country] => US
[patent_app_date] => 2021-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36984
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266706
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/266706 | METHODS OF TREATING DIABETES | Dec 13, 2021 | Pending |
Array
(
[id] => 19601087
[patent_doc_number] => 20240391967
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => METHODS AND USES FOR NDFIP1 FUSION POLYPEPTIDES IN TREATING NEURODEGENERATIVE DISEASES, BRAIN AND/OR TRAUMATIC AND NON-TRAUMATIC SPINAL CORD INJURIES, AND/OR OPTIC NEUROPATHIES
[patent_app_type] => utility
[patent_app_number] => 18/255136
[patent_app_country] => US
[patent_app_date] => 2021-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13233
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255136
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/255136 | METHODS AND USES FOR NDFIP1 FUSION POLYPEPTIDES IN TREATING NEURODEGENERATIVE DISEASES, BRAIN AND/OR TRAUMATIC AND NON-TRAUMATIC SPINAL CORD INJURIES, AND/OR OPTIC NEUROPATHIES | Dec 1, 2021 | Pending |